Categories

Подкатегории

Active filters

Zevalin, 1.6 mg / ml
€18,850.00
Zometa ,4MG/100ML
€262.22
JANSSEN,Darzalex (Daratumumab) ,100 mg / 5ml, 1pcs
JANSSEN,Darzalex (Daratumumab) ,400 mg / 20ml, 1pcs
€2,637.70
LITAK, 2MG/ML  5 ML
€584.97
NOVARTIS,Jakavi (Ruxolitinib) ,20 mg, 56 tablets
€5,139.68
NOVARTIS,Jakavi (Ruxolitinib) ,5 mg, 56 tablets
€2,607.12
NOVARTIS,Jakavi (Ruxolitinib) ,15 mg, 56 tablets
€5,139.68
Zaltrap, 8 ml
€1,043.65
Zaltrap, 4 ml
€622.45
SANOFI ,Jevtana (Cabazitaxel) ,60 mg ,1 Bottle
€5,153.58

Semisynthetic antitumor agent of plant origin, obtained by chemical synthesis from natural raw materials - European yew needles (Taxus baccata). White or almost white powder, highly lipophilic and practically insoluble in water. The molecular weight of 861.9.

Semisynthetic antitumor agent of plant origin, obtained by chemical synthesis from natural raw materials - European yew needles (Taxus baccata). White or almost white powder, highly lipophilic and practically insoluble in water. The molecular weight of 861.9.

The active substance is Mercapturin. It is capable of exerting both antitumor and immunosuppressive effects. It quickly penetrates into the tumor, thereby its further growth stops.

prescription

Manufacturer Aspen Germany GmbH Germany

The drug is a medicine that suppresses the effects of male sex hormone (testosterone) (non-steroidal antiandrogen).

Used to treat locally advanced prostate cancer and a high risk of disease progression.

The drug is a medicine that suppresses the effects of male sex hormone (testosterone) (non-steroidal antiandrogen).

Used to treat locally advanced prostate cancer and a high risk of disease progression.

€18,850.00

treatment of recurrent or refractory CD20-positive indolent B-cell non-Hodgkin lymphoma in adult patients;

consolidation therapy after achieving remission in previously untreated patients with follicular lymphoma.

The use of the substance Afatinib

Afatinib is indicated as monotherapy to patients who have not previously received tyrosine kinase inhibitors for the treatment of locally advanced or metastatic non-small cell lung cancer with a mutation (mutations) of the epidermal growth factor receptor

on prescription

Manufacturer Boehringer Ingelheim

Kisplyx (Kisplyx) is indicated in combination with everolimus for the treatment of adult patients with renal cell carcinoma (PAC) after one previous vascular endothelial growth factor (VEGF) -targeted therapy.

Kisplyx (Kisplyx) is indicated in combination with everolimus for the treatment of adult patients with renal cell carcinoma (PAC) after one previous vascular endothelial growth factor (VEGF) -targeted therapy.

€262.22

The active substance in the drug is called zoledronic acid and is a representative of a group of substances called bisphosphonates. Zoledronic acid works by binding to bones and slowing down the speed of bone remodeling.

The specific antidote of paclitaxel is unknown. In case of an overdose of the drug Abraksan, symptomatic treatment and careful monitoring of the patient are carried out. Treatment should be directed to the main predictable complications (myelosuppression, mucositis, and peripheral neuropathy).

 

on prescription

Manufacturer Fresenius Kabi

Idelalisib (idelalisib) is used to treat relapsing chronic lymphocytic leukemia, relapsing follicular non-Hodgkin B-cell lymphoma, and small cell lymphocytic lymphoma. Sidelig is used in combination with rituximab (rituximab).

1 ml of concentrate contains: active substance: daratumumab - 20 mg; excipients: glacial acetic acid - 0.186 mg, sodium acetate trihydrate - 2.967 mg, sodium chloride - 3.506 mg, mannitol - 25.500 mg, polysorbate-20 - 0.400 mg, water for injection - up to 1.0 ml

€2,637.70

1 ml of concentrate contains: active substance: daratumumab - 20 mg; excipients: glacial acetic acid - 0.186 mg, sodium acetate trihydrate - 2.967 mg, sodium chloride - 3.506 mg, mannitol - 25.500 mg, polysorbate-20 - 0.400 mg, water for injection - up to 1.0 ml

€584.97

Litak is intended for the treatment of hairy cell leukemia. Litak solution is indicated as a second-line drug for the treatment of patients with recurrent or non-treatable lymphoproliferative diseases of low malignancy, such as follicular and diffuse non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Valdenström macroglobulinemia.

The multicomponent composition regimens: osteogenic sarcoma, uterine sarcoma, lymphosarcoma, embryonal rhabdomyosarcoma, and pleural mesothelioma of the peritoneum, carcinoid tumors (including bronchogenic carcinoma, small cell lung cancer, thyroid cancer), pheochromocytoma, insulinoma, neuroblastoma, CNS tumor (glioma).

The multicomponent composition regimens: osteogenic sarcoma, uterine sarcoma, lymphosarcoma, embryonal rhabdomyosarcoma, and pleural mesothelioma of the peritoneum, carcinoid tumors (including bronchogenic carcinoma, small cell lung cancer, thyroid cancer), pheochromocytoma, insulinoma, neuroblastoma, CNS tumor (glioma).

The multicomponent composition regimens: osteogenic sarcoma, uterine sarcoma, lymphosarcoma, embryonal rhabdomyosarcoma, and pleural mesothelioma of the peritoneum, carcinoid tumors (including bronchogenic carcinoma, small cell lung cancer, thyroid cancer), pheochromocytoma, insulinoma, neuroblastoma, CNS tumor (glioma).

Kaitruda is the brightest representative of the monoclonal antibody group. Numerous clinical studies, practical experience with Keitruda, reviews of oncologists and patients suggest the uniqueness of this drug. Its feature is the ability to obtain favorable results even in the treatment of metastatic forms of malignant tumors

The introduction of enzyme combinations is a proven method of supporting the immune system for many decades. An additional balanced diet Wobe-Mucos is designed for dietary treatment of cancer patients during and after chemotherapy and radiation therapy.

The introduction of enzyme combinations is a proven method of supporting the immune system for many decades. An additional balanced diet Wobe-Mucos is designed for dietary treatment of cancer patients during and after chemotherapy and radiation therapy.

In August 2017, the EU approved Novartis AG's Kisqali (ribocyclib) as the first line of treatment for breast cancer.

€5,139.68

treatment of patients with myelofibrosis, including primary myelofibrosis and secondary myelofibrosis, developed as a result of true polycythemia and essential thrombocythemia.

€2,607.12

treatment of patients with myelofibrosis, including primary myelofibrosis and secondary myelofibrosis, developed as a result of true polycythemia and essential thrombocythemia.

Zikadia has been developed for the treatment of non-small cell lung cancer, which has positive anaplastic lymphoma kinase with the ineffectiveness of other methods. The positive effect was confirmed after a series of trials on living patients.

In August 2017, the EU approved Novartis AG's Kisqali (ribocyclib) as the first line of treatment for breast cancer.

€5,139.68

treatment of patients with myelofibrosis, including primary myelofibrosis and secondary myelofibrosis, developed as a result of true polycythemia and essential thrombocythemia.

A side effect of Axitinib (Inlita) is an undesirable reaction to the drug when taking a standard dosage. If you are concerned about side effects, talk with your doctor about the risks and benefits of this medicine. Rare adverse events occurring in up to 1% of cases (abdominal pain, constipation, cough, dizziness, hoarseness, itching of the skin, pain in the limbs, ringing in the ears, vomiting) can go away on their own.

over the counter

Manufacturer PFIZER

intoxication with folic acid antagonists (methotrexate, trimethoprim, pyrimethamine);

prevention of the toxic effects of methotrexate when used in high and high doses;

colorectal cancer (as part of complex therapy with fluorouracil)

Lymphoblastic leukemia, soft tissue sarcoma, osteogenic sarcoma, Ewing's sarcoma, breast cancer, thyroid cancer, Wilms tumor, neuroblastoma, bladder cancer, stomach cancer, ovarian cancer, lymphogranulomatosis, non-Hodgkin lymphoma, trophoblastic tumors.

Taking the medicine may be accompanied by a feeling of fatigue, swelling, muscle pain, dyspeptic disorders, constipation, shortness of breath, coughing, headaches and back pain. Sometimes taking the drug is accompanied by the development of abdominal pain, bradycardia, pneumonia, interstitial lung diseases, weakness, and loss of appetite.

over the counter

Manufacturer Roche Pharma

Patients with lymphoma and multiple myeloma to enhance the mobilization of hematopoietic stem cells into the peripheral bloodstream to collect them and subsequent autotransplantation in combination with G-CSF

€1,043.65

Concentrate for solution for infusion, 100 mg / 4 ml and 200 mg / 8 ml

Description

Transparent colorless or pale yellow liquid, free from mechanical impurities.

€622.45

Concentrate for solution for infusion, 100 mg / 4 ml and 200 mg / 8 ml

Description

Transparent colorless or pale yellow liquid, free from mechanical impurities.

€5,153.58

Jevtana is the latest generation cytotoxic drug. According to the active substance, Cabazitaxel, the Dzhevtan preparation belongs to antitumor alkaloids - biological medicines of natural origin. Cabazitaxel has a destructive effect on tumor cells. Suppressing the activity of the tubulin protein, which is part of the intracellular protein structures - microtubules, Dzhevtana inhibits the process of division of tumor cells.

Before starting the treatment course, you need to familiarize yourself with the provisions of the annotation to the drug. Failure to comply with the recommendations set forth in the instructions for use can lead to a decrease in the effectiveness of the therapy and the development of serious side effects.

on prescription

Manufacturer Teva Israel

Androgens, antiandrogens

Antitumor hormones and hormone antagonists

prescription

Manufacturer Teva GmbH Germany

Patient Notes

Warnings and Precautions

Please talk with your doctor or pharmacist before taking the medicine:

If you have moderate or severe liver problems

If you have diabetes and are already taking LHRH agonists (e.g., goserelin, buserelin, leuprorelin and triptorelin).

Before taking this medicine, please tell your doctor if you have any diseases or problems with the liver.

 

on prescription

Manufacturer TEVA GmbH

Patient Notes

Warnings and Precautions

Please talk with your doctor or pharmacist before taking the medicine:

If you have moderate or severe liver problems

If you have diabetes and are already taking LHRH agonists (e.g., goserelin, buserelin, leuprorelin and triptorelin).

Before taking this medicine, please tell your doctor if you have any diseases or problems with the liver.

 

on prescription

Manufacturer TEVA GmbH

Dietary supplements

Under the order

{gformbuilderpro:1}